CYP2C19 · rs12248560
Where this position leads
Drug: Clopidogrel
Source: CPIC Guideline for CYP2C19 Genotype and Clopidogrel Therapy: 2022 Update, Clinical Pharmacology & Therapeutics (PMID 35034351).
What people read about alongside this
Papers in Europe PMC whose title or abstract names both this rsID and that subject. A shared paper means somebody wrote about the two together — it is not a claim that this position explains the subject.
rs12248560 is a single position in the genome, in or near the CYP2C19 gene. Published research associates it with cyp2c19 *17 — increased enzyme activity. A single variant does not decide an outcome — it shifts a probability, and for most common variants the shift is small.
CYP2C19 carries pharmacogenomic findings for Clopidogrel. That is educational information, not a prescription or a dosing guide. Any decision to start, stop or change a medicine belongs with the clinician or pharmacist managing your treatment.
Subjects that appear in the title or abstract of the same papers as this rsID include depression and stress (2 papers). A shared paper means somebody wrote about the two together; it is not a claim that this position explains the topic.
No. Common variants like this one move a probability slightly and, on their own, rarely decide anything about one person. Nothing on this page is a diagnosis, and health decisions should be made with a clinician who can see your whole picture.
CPIC Guideline for CYP2C19 Genotype and Clopidogrel Therapy: 2022 Update, Clinical Pharmacology & Therapeutics (PMID 35034351). Every variant on MyGeneLog comes from public primary sources and is published with its citation and the date it was checked.